Using Hybrid APC to treat gastric low grade intraepithelial neoplasia
HybridAPC for the Treatment of Gastric Low Grade Intraepithelial Neoplasia (LGIN): a Prospective, Multi-center Study
This study is testing if a new treatment called Hybrid Argon Plasma Coagulation can safely remove low-grade stomach growths and prevent them from coming back in people who have these conditions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT04197180 on ClinicalTrials.gov |
What this trial studies
This cohort study investigates the clinical efficacy and safety of Hybrid Argon Plasma Coagulation (APC) for treating gastric low grade intramucosal neoplasia. The study aims to achieve successful ablation, defined as no local recurrence of neoplasia at 12 months post-treatment, verified through follow-up endoscopy and biopsies. Eligible patients will have confirmed gastric low grade intraepithelial neoplasia and will undergo the Hybrid APC procedure under informed consent.
Who should consider this trial
Good fit: Ideal candidates are patients with biopsy-confirmed gastric low grade intraepithelial neoplasia measuring 20 mm or less.
Not a fit: Patients with high grade intraepithelial neoplasia, previous endoscopic treatments, or other significant gastrointestinal conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a minimally invasive option for patients with gastric low grade intraepithelial neoplasia, potentially reducing the risk of progression to cancer.
How similar studies have performed: Other studies have shown promising results with similar endoscopic ablation techniques, suggesting potential efficacy for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Low grade intraepithelial neoplasia of stomach with size≤20 mm 2. Endoscopic diagnosis suspected gastric LGIN with biopsy confirmed gastric LGIN 3. Endoscopic appearance according to Paris classification of Type 0-IIa, IIb or IIc 4. Patients with informed consent Exclusion Criteria: 1. Patients who had previous endoscopic treatment (including APC, EMR, ESD) for gastric LGIN, HGIN or gastric carcinoma. 2. Endoscopic evidence of ulcer 3. Biopsy confirmed HGIN 4. Endoscopic diagnosis suspected HGIN while biopsy confirmed LGIN 5. Pregnancy 6. informed consent not available
Where this trial is running
Hong Kong
- Combined Endoscopy Center, Prince of Wales Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Philip WY Chiu, MD — Chinese University of Hong Kong
- Study coordinator: Philip WU Chiu, MD
- Email: philipchiu@surgery.cuhk.edu.hk
- Phone: +85235053952
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.